**Deals and M&A Biotech and Medtech**

**1st Semester 2017**

- **503 deals worldwide**
  - Oncology (36%)
  - Neurology (11%)
  - Metabolism (9%)
  - Infectious diseases (9%)
  - Cardiovascular (2%)
  - Pulmonary (2%)
  - Others (3%)

- **37% of deals for biologics**
  - 22% for small molecules

- **Total worth > 35 Bn$**
  - Average deal value: 378 M$  
  - 36% of deals in oncology
  - 11% in neurology
  - > 1/3 of deals are licensing agreements
  - 36% antibodies
  - 15% cell therapy
  - 12% protein/peptide
  - 10% biomarker

**American companies are present in 9 out of 10 top deals**

Top 3 deals worldwide:
1. **2.85 Bn$**
   - Stage: phase II
   - Company: AbbVie
2. **2.83 Bn$**
   - Stage: phase II
   - Company: Amgen
3. **2.15 Bn$**
   - Stage: phase II
   - Company: Biogen

Top 3 deals with French biotech:
1. **460 M$**
   - Stage: phase II
   - Company: Genevrier
2. **237 M$**
   - Stage: phase II
   - Company: Celyad
3. **242 M$**
   - Stage: phase II
   - Company: T-cellxa

**60 M&A operations worldwide**

- 47 acquisitions
- 13 mergers

Main therapeutic areas of companies:
- 25% in oncology
- 18% in neurology
- 9% infectious diseases

- **52% for biologics**
  - 25% for small molecules

**1st Semester 2017**

- **Total worth > 49 Bn$**
  - Average deal value: 1.7 Bn$  
  - Stage of target company at signing:
    - Preclinical in phase (23%)
    - Less than Phase II (30%)
    - Phase II or earlier (47%)

- 26% protein/peptide
- 21% antibodies
- 16% vaccine

Top 3 M&A operations (full acquisitions):
1. **30 Bn$**
   - Company: Actelion
   - Bought by: Johnson & Johnson
2. **5.2 Bn$**
   - Company: AMRI
   - Bought by: Takeda
3. **4.3 Bn$**
   - Company: Akorn
   - Bought by: Fresenius